Secondary hyperparathyroidism in chronic kidney disease: pathophysiology, current treatments and investigational drugs

References

• Goltzman D, Mannstadt M, Marcocci C. Physiology of the calcium-parathyroid hormone-vitamin D Axis. Vit D Clinic Med. 2018;50:1–13.
   Web of Science ®Google Scholar
• Habener JF. Regulation of parathyroid-hormone secretion and biosynthesis. Annu Rev Physiol. 1981;43(1):211–223. doi: 10.1146/annurev.ph.43.030181.001235
   PubMedGoogle Scholar
• Wein MN, Kronenberg HM. Regulation of bone remodeling by parathyroid hormone. Cold Spring Harb Perspect Med. 2018 Aug;8(8):a031237. doi: 10.1101/cshperspect.a031237
   PubMed Web of Science ®Google Scholar
• Brenza HL, Kimmel-Jehan C, Jehan F, et al. Parathyroid hormone activation of the 25-hydroxyvitamin D3-1alpha-hydroxylase gene promoter. Proc Natl Acad Sci USA. 1998 Feb 17;95(4):1387–1391. doi: 10.1073/pnas.95.4.1387
   PubMed Web of Science ®Google Scholar
• Alexander RT, Dimke H. Effects of parathyroid hormone on renal tubular calcium and phosphate handling. Acta Physiol. 2023 May;238(1). doi: 10.1111/apha.13959
   PubMed Web of Science ®Google Scholar
• McCann LM, Beto J. Roles of calcium-sensing receptor and vitamin D receptor in the pathophysiology of secondary hyperparathyroidism. J Ren Nutr. 2010 May;20(3):141–150. doi: 10.1053/j.jrn.2010.01.004
   PubMed Web of Science ®Google Scholar
• Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011 Apr;6(4):913–921. doi: 10.2215/CJN.06040710
   PubMed Web of Science ®Google Scholar
• Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007 Jan;71(1):31–38. doi: 10.1038/sj.ki.5002009
   PubMed Web of Science ®Google Scholar
• Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011 Jun;79(12):1370–1378. doi: 10.1038/ki.2011.47
   PubMed Web of Science ®Google Scholar
• Magagnoli L, Cozzolino M, Caskey FJ, et al. Association between CKD-MBD and mortality in older patients with advanced CKD—results from the EQUAL study. Nephrol Dialysis Transplantation. 2023 May;38(11):2562–2575. doi: 10.1093/ndt/gfad100
   PubMed Web of Science ®Google Scholar
• Floege J, Kim J, Ireland E, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant. 2011 Jun;26(6):1948–1955. doi: 10.1093/ndt/gfq219
   PubMed Web of Science ®Google Scholar
• Noordzij M, Korevaar JC, Boeschoten EW, et al. The kidney disease outcomes quality initiative (K/DOQI) guideline for bone metabolism and disease in CKD: association with mortality in dialysis patients. Am J Kidney Diseases. 2005;46(5):925–932. doi: 10.1053/j.ajkd.2005.08.013
   PubMed Web of Science ®Google Scholar
• Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis. 2008 Sep;52(3):519–530. doi: 10.1053/j.ajkd.2008.03.020
   PubMed Web of Science ®Google Scholar
• Kovesdy CP, Ahmadzadeh S, Anderson JE, et al. Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int. 2008 Jun;73(11):1296–1302. doi: 10.1038/ki.2008.64
   PubMed Web of Science ®Google Scholar
• Geng S, Kuang Z, Peissig PL, et al. Parathyroid hormone independently predicts fracture, vascular events, and death in patients with stage 3 and 4 chronic kidney disease. Osteoporos Int. 2019 Oct;30(10):2019–2025. doi: 10.1007/s00198-019-05033-3
   PubMed Web of Science ®Google Scholar
• Group KDIGOKC-MW. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009;76:S1–S130.
   Google Scholar
• Group KDIGOKC-MUW. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017 Jul;7(1):1–59. doi: 10.1016/j.kisu.2017.04.001
   Web of Science ®Google Scholar
• Hassan A, Khalaily N, Kilav-Levin R, et al. Molecular mechanisms of parathyroid disorders in chronic kidney disease. Metabolites. 2022 Feb;12(2):111. doi: 10.3390/metabo12020111
   PubMed Web of Science ®Google Scholar
• Brown EM, Gamba G, Riccardi D, et al. Cloning And characterization of an extracellular Ca2±sensing receptor from bovine parathyroid. Nature. 1993 Dec;366(6455):575–580. doi: 10.1038/366575a0
   PubMed Web of Science ®Google Scholar
• Hofer AM, Brown EM. Extracellular calcium sensing and signalling. Nat Rev Mol Cell Biol. 2003 Jul;4(7):530–538. doi: 10.1038/nrm1154
   PubMed Web of Science ®Google Scholar
• Chavez-Abiega S, Mos I, Centeno PP, et al. Sensing extracellular calcium - an insight into the structure and function of the calcium-sensing receptor (CaSR). Calcium Signaling, 2nd Ed. 2020;1131:1031–1063.
   Google Scholar
• Centeno PP, Herberger A, Mun HC, et al. Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion. Nat Commun. 2019 Oct 10;10(1). doi: 10.1038/s41467-019-12399-9
   PubMedGoogle Scholar
• Chen RA, Goodman WG. Role of the calcium-sensing receptor in parathyroid gland physiology. Am J Physiol Renal Physiol. 2004 Jun;286(6):F1005–F1011. doi: 10.1152/ajprenal.00013.2004
   PubMed Web of Science ®Google Scholar
• Kifor O, Moore FD, Wang P, et al. Reduced immunostaining for the extracellular Ca sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab. 1996 Apr;81(4):1598–1606. doi: 10.1210/jc.81.4.1598
   PubMed Web of Science ®Google Scholar
• Brown AJ, Zhong M, Finch J, et al. Rat calcium-sensing receptor is regulated by vitamin D but not by calcium. Am J Physiol-Renal Fluid And Electrolyte Physiol. 1996 Mar;270(3):F454–F460. doi: 10.1152/ajprenal.1996.270.3.F454
   PubMed Web of Science ®Google Scholar
• Fetahua IS, Hummel DM, Manhardt T, et al. Regulation of the calcium-sensing receptor expression by 1,25-dihydroxyvitamin D3, interleukin-6, and tumor necrosis factor alpha in colon cancer cells. J Steroid Biochem Mol Biol. 2014 Oct;144:228–231. doi: 10.1016/j.jsbmb.2013.10.015
   PubMed Web of Science ®Google Scholar
• Canaff L, Hendy GN. Human calcium-sensing receptor gene - vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D. J Biol Chem. 2002 Aug;277(33):30337–30350. doi: 10.1074/jbc.M201804200
   PubMed Web of Science ®Google Scholar
• LaClair RE, Hellman RN, Karp SL, et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Diseases. 2005 Jun;45(6):1026–1033. doi: 10.1053/j.ajkd.2005.02.029
   PubMed Web of Science ®Google Scholar
• Nitta K, Nagano N, Tsuchiya K. Fibroblast growth factor 23/Klotho axis in chronic kidney disease. Nephron Clin Pract. 2014 Dec;128(1–2):1–10. doi: 10.1159/000365787
   PubMed Web of Science ®Google Scholar
• Baker AR, McDonnell DP, Hughes M, et al. Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci, USA. 1988 May;85(10):3294–3298. doi: 10.1073/pnas.85.10.3294
   PubMed Web of Science ®Google Scholar
• Gallieni M, Cozzolino M, Fallabrino G, et al. Vitamin D: physiology and pathophysiology. Int J Of Artificial Organs. 2009 Feb;32(2):87–94. doi: 10.1177/039139880903200205
   PubMed Web of Science ®Google Scholar
• Bikle D, Christakos S. New aspects of vitamin D metabolism and action - addressing the skin as source and target. Nat Rev Endocrinol. 2020 Apr;16(4):234–252. doi: 10.1038/s41574-019-0312-5
   PubMed Web of Science ®Google Scholar
• Nishishita T, Okazaki T, Ishikawa T, et al. A negative vitamin D response DNA element in the human parathyroid hormone-related peptide gene binds to vitamin D receptor along with Ku antigen to mediate negative gene regulation by vitamin D. J Biol Chem. 1998 May;273(18):10901–10907. doi: 10.1074/jbc.273.18.10901
   PubMed Web of Science ®Google Scholar
• Dusso A, Cozzolino M, Lu Y, et al. 1,25-Dihydroxyvitamin D downregulation of TGFα/EGFR expression and growth signaling: a mechanism for the antiproliferative actions of the sterol in parathyroid hyperplasia of renal failure. J Steroid Biochem Mol Biol. 2004 May;89-90(1–5):507–511. doi: 10.1016/j.jsbmb.2004.03.061
   PubMed Web of Science ®Google Scholar
• Fukuda N, Tanaka H, Tominaga Y, et al. Decreased 1,25-dihydroxyvitamin-D(3) receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Investig. 1993 Sep;92(3):1436–1443. doi: 10.1172/JCI116720
   PubMed Web of Science ®Google Scholar
• Penido M, Alon US. Phosphate homeostasis and its role in bone health. Pediatr Nephrol. 2012 Nov;27(11):2039–2048. doi: 10.1007/s00467-012-2175-z
   PubMed Web of Science ®Google Scholar
• Wagner CA. The basics of phosphate metabolism. Nephrol Dialysis Transplantation. 2023;39(2):190–201. doi: 10.1093/ndt/gfad188
   Web of Science ®Google Scholar
• Bon N, Couasnay G, Bourgine A, et al. Phosphate (Pi)-regulated heterodimerization of the high-affinity sodium-dependent Pi transporters PiT1/Slc20a1 and PiT2/Slc20a2 underlies extracellular Pi sensing independently of Pi uptake. J Biol Chem. 2018 Feb;293(6):2102–2114. doi: 10.1074/jbc.M117.807339
   PubMed Web of Science ®Google Scholar
• Liu SG, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol. 2007 Jun;18(6):1637–1647. doi: 10.1681/ASN.2007010068
   PubMed Web of Science ®Google Scholar
• Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006 Dec;444(7120):770–774. doi: 10.1038/nature05315
   PubMed Web of Science ®Google Scholar
• Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Investig. 2007 Dec;117(12):4003–4008. doi: 10.1172/JCI32409
   PubMed Web of Science ®Google Scholar
• Krajisnik T, Bjorklund P, Marsel R, et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1α-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol. 2007 Oct;195(1):125–131. doi: 10.1677/JOE-07-0267
   PubMed Web of Science ®Google Scholar
• Canalejo R, Canalejo A, Martinez-Moreno JM, et al. FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol. 2010 Jul;21(7):1125–1135. doi: 10.1681/ASN.2009040427
   PubMed Web of Science ®Google Scholar
• Galitzer H, Ben-Dov IZ, Silver J, et al. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int. 2010 Feb;77(3):211–218. doi: 10.1038/ki.2009.464
   PubMed Web of Science ®Google Scholar
• Komaba H, Goto S, Fujii H, et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int. 2010 Feb;77(3):232–238. doi: 10.1038/ki.2009.414
   PubMed Web of Science ®Google Scholar
• Kawakami K, Takeshita A, Furushima K, et al. Persistent fibroblast growth factor 23 signalling in the parathyroid glands for secondary hyperparathyroidism in mice with chronic kidney disease. Sci Rep. 2017 Jan 17;7(1):40534. doi: 10.1038/srep40534
   PubMedGoogle Scholar
• Sela-Brown A, Silver J, Brewer G, et al. Identification of AUF1 as a parathyroid hormone mRNA 3′-untranslated region-binding protein that determines parathyroid hormone mRNA stability. J Biol Chem. 2000 Mar;275(10):7424–7429. doi: 10.1074/jbc.275.10.7424
   PubMed Web of Science ®Google Scholar
• Nechama M, Ben-Dov IZ, Briata P, et al. The mRNA decay promoting factor K-homology splicing regulator protein post-transcriptionally determines parathyroid hormone mRNA levels. FASEB J. 2008 Oct;22(10):3458–3468. doi: 10.1096/fj.08-107250
   PubMed Web of Science ®Google Scholar
• Nechama M, Uchida T, Yosef-Levi IM, et al. The peptidyl-prolyl isomerase Pin1 determines parathyroid hormone mRNA levels and stability in rat models of secondary hyperparathyroidism. J Clin Investig. 2009 Oct;119(10):3102–3114. doi: 10.1172/JCI39522
   PubMed Web of Science ®Google Scholar
• Shilo V, Ben-Dov IZ, Nechama M, et al. Parathyroid-specific deletion of dicer-dependent microRnas abrogates the response of the parathyroid to acute and chronic hypocalcemia and uremia. FASEB J. 2015 Sep;29(9):3964–3976. doi: 10.1096/fj.15-274191
   PubMed Web of Science ®Google Scholar
• Shilo V, Levi IMY, Abel R, et al. Let-7 and MicroRNA-148 regulate parathyroid hormone levels in secondary hyperparathyroidism. J Am Soc Nephrol. 2017 Aug;28(8):2353–2363. doi: 10.1681/ASN.2016050585
   PubMed Web of Science ®Google Scholar
• Wang Q, Palnitkar S, Parfitt AM. Parathyroid cell proliferation in the rat: Effect of age and of phosphate administration and recovery. Endocrinology. 1996 Nov;137(11):4558–4562. doi: 10.1210/endo.137.11.8895317
   PubMed Web of Science ®Google Scholar
• Tominaga Y, Kohara S, Namii Y, et al. Clonal analysis of nodular parathyroid hyperplasia in renal hyperparathyroidism. World J Surg. 1996 Sep;20(7):744–752. doi: 10.1007/s002689900113
   PubMed Web of Science ®Google Scholar
• Tokumoto M, Tsuruya K, Fukuda K, et al. Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism. Kidney Int. 2002 Oct;62(4):1196–1207. doi: 10.1111/j.1523-1755.2002.kid585.x
   PubMed Web of Science ®Google Scholar
• Arcidiacono MV, Yang J, Fernandez E, et al. Parathyroid-specific epidermal growth factor-receptor inactivation prevents uremia-induced parathyroid hyperplasia in mice. Nephrol Dialysis Transplantation. 2015 Mar;30(3):434–440. doi: 10.1093/ndt/gfu318
   PubMed Web of Science ®Google Scholar
• Volovelsky O, Cohen G, Kenig A, et al. Phosphorylation of ribosomal protein S6 mediates mammalian target of rapamycin complex 1-induced parathyroid cell proliferation in secondary hyperparathyroidism. J Am Soc Nephrol. 2016 Apr;27(4):1091–1101. doi: 10.1681/ASN.2015040339
   PubMed Web of Science ®Google Scholar
• Zhang QA, Qiu JS, Li HM, et al. Cyclooxygenase 2 promotes parathyroid hyperplasia in ESRD. J Am Soc Nephrol. 2011 Apr;22(4):664–672. doi: 10.1681/ASN.2010060594
   PubMed Web of Science ®Google Scholar
• Lou LM, Caverni A, Gimeno JA, et al. Dietary intervention focused on phosphate intake in hemodialysis patients with hyperphosphatemia. Clin Nephrol. 2012 Jun;77(6):476–483.
   PubMed Web of Science ®Google Scholar
• Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013 Oct;382(9900):1268–1277. doi: 10.1016/S0140-6736(13)60897-1
   PubMed Web of Science ®Google Scholar
• Pergola PE, Rosenbaum DP, Yang Y, et al. A randomized trial of tenapanor and phosphate binders as a dual-mechanism treatment for hyperphosphatemia in patients on maintenance dialysis (AMPLIFY). J Am Soc Nephrol. 2021 Jun;32(6):1465–1473. doi: 10.1681/ASN.2020101398
   PubMed Web of Science ®Google Scholar
• Lin T, Al-Makki A, Shepler B. Tenapanor: a new treatment option for hyperphosphatemia in end stage kidney disease. J Pharm Pharm Sci. 2022;25:77–83. doi: 10.18433/jpps32284
   PubMed Web of Science ®Google Scholar
• Daugirdas JT. Removal of phosphorus by hemodialysis. Semin Dial. 2015 Nov;28(6):620–623. doi: 10.1111/sdi.12439
   PubMed Web of Science ®Google Scholar
• Memmos DE, Eastwood JB, Talner LB, et al. Double-blind trial of oral 1,25-dihydroxy vitamin-D3 Versus placebo in asymptomatic hyperparathyroidism in patients receiving maintenance hemodialysis. Br Med J. 1981;282(6280):1919–1924. doi: 10.1136/bmj.282.6280.1919
   PubMedGoogle Scholar
• Galassi A, Ciceri P, Porata G, et al. Current treatment options for secondary hyperparathyroidism in patients with stage 3 to 4 chronic kidney disease and vitamin D deficiency. Expert Opin Drug Saf. 2021 Nov;20(11):1333–1349. doi: 10.1080/14740338.2021.1931117
   PubMed Web of Science ®Google Scholar
• Cuppari L, Garcia-Lopes MG. Hypovitaminosis D in chronic kidney disease patients: prevalence and treatment. J Ren Nutr. 2009 Jan;19(1):38–43. doi: 10.1053/j.jrn.2008.10.005
   PubMed Web of Science ®Google Scholar
• Bischoff-Ferrari HA, Dawson-Hughes B, Stöcklin E, et al. Oral supplementation with 25(OH)D3 versus vitamin D3: Effects on 25(OH)D levels, lower extremity function, blood pressure, and markers of innate immunity. J Bone Mineral Res. 2012 Jan;27(1):160–169. doi: 10.1002/jbmr.551
   PubMed Web of Science ®Google Scholar
• Sprague SM, Crawford PW, Melnick JZ, et al. Use of extended-release calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Am J Nephrol. 2016;44(4):316–325. doi: 10.1159/000450766
   PubMed Web of Science ®Google Scholar
• Martin KJ, González EA, Gellens M, et al. 19-nor-1-α-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol. 1998 Aug;9(8):1427–1432. doi: 10.1681/ASN.V981427
   PubMed Web of Science ®Google Scholar
• Frazao JM, Elangovan L, Maung HM, et al. Intermittent doxercalciferol (1α-hydroxyvitamin D2) therapy for secondary hyperparathyroidism. Am J Kidney Diseases. 2000 Sep;36(3):550–561. doi: 10.1053/ajkd.2000.16193
   PubMed Web of Science ®Google Scholar
• Kazama JJ, Maruyama H, Narita I, et al. Maxacalcitol is a possible less phosphatemic vitamin D analog. Ther Apher Dial. 2005 Aug;9(4):352–354. doi: 10.1111/j.1744-9987.2005.00296.x
   PubMed Web of Science ®Google Scholar
• Nemeth EF, Fox J. Calcimimetic compounds: a direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism. Trends Endocrinol Metab. 1999 Mar;10(2):66–71. doi: 10.1016/S1043-2760(98)00119-2
   PubMed Web of Science ®Google Scholar
• Block GA, Martin KJ, de Francisco ALM, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004 Apr;350(15):1516–1525. doi: 10.1056/NEJMoa031633
   PubMed Web of Science ®Google Scholar
• Block GA, Bushinsky DA, Cunningham J, et al. Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism two randomized clinical trials. JAMA-J Am Med Assoc. 2017 Jan;317(2):146–155. doi: 10.1001/jama.2016.19456
   PubMed Web of Science ®Google Scholar
• Hou YC, Zheng CM, Chiu HW, et al. Role of calcimimetics in treating bone and mineral disorders related to chronic kidney disease. Pharmaceuticals. 2022 Aug;15(8):952. doi: 10.3390/ph15080952
   Web of Science ®Google Scholar
• Franceschini N, Joy MS, Kshirsagar A. Cinacalcet HCI: a calcimimetic agent for the management of primary and secondary hyperparathyroidism. Expert Opin Investig Drugs. 2003 Aug;12(8):1413–1421. doi: 10.1517/13543784.12.8.1413
   PubMed Web of Science ®Google Scholar
• Ballinger AE, Palmer SC, Nistor I, et al. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev. 2014;2014(12). doi: 10.1002/14651858.CD006254.pub2
   PubMedGoogle Scholar
• Harris RZ, Salfi M, Posvar E, et al. Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol. 2007 Feb;63(2):159–163. doi: 10.1007/s00228-006-0129-8
   PubMed Web of Science ®Google Scholar
• Block GA, Bushinsky DA, Cheng SF, et al. Effect Of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism a randomized clinical trial. JAMA-J Am Med Assoc. 2017 Jan;317(2):156–164. doi: 10.1001/jama.2016.19468
   PubMed Web of Science ®Google Scholar
• Fukagawa M, Shimazaki R, Akizawa T, et al. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int. 2018 Oct;94(4):818–825. doi: 10.1016/j.kint.2018.05.013
   PubMed Web of Science ®Google Scholar
• Ni ZH, Liang XL, Wu CC, et al. Comparison of the oral calcimimetics evocalcet and cinacalcet in east asian patients on hemodialysis with secondary hyperparathyroidism. Kidney Int Rep. 2023 Nov;8(11):2294–2306. doi: 10.1016/j.ekir.2023.08.034
   PubMed Web of Science ®Google Scholar
• Sato H, Murakami S, Horii Y, et al. Upacicalcet is a novel secondary hyperparathyroidism drug that targets the amino acid binding site of calcium-sensing receptor. Mol Pharmacol. 2022 Oct;102(4):183–195. doi: 10.1124/molpharm.122.000522
   PubMed Web of Science ®Google Scholar
• Shigematsu T, Koiwa F, Isaka Y, et al. Efficacy and safety of upacicalcet in hemodialysis patients with secondary hyperparathyroidism a randomized placebo-controlled trial. CJASN. 2023 Sep;18(10):1300–1309. doi: 10.2215/CJN.0000000000000253
   PubMed Web of Science ®Google Scholar
• Lafrance JP, Cardinal H, Leblanc M, et al. Effect of cinacalcet availability and formulary listing on parathyroidectomy rate trends. BMC Nephrol. 2013 May 14;14(1). doi: 10.1186/1471-2369-14-100
   PubMedGoogle Scholar
• Cianciolo G, Tondolo F, Barbuto S, et al. A roadmap to parathyroidectomy for kidney transplant candidates. Clin Kidney J. 2022 Jul;15(8):1459–1474. doi: 10.1093/ckj/sfac050
   PubMed Web of Science ®Google Scholar
• Lorenz K, Bartsch DK, Sancho JJ, et al. Surgical management of secondary hyperparathyroidism in chronic kidney disease—a consensus report of the European society of endocrine surgeons. Langenbecks Arch Surg. 2015 Dec;400(8):907–927. doi: 10.1007/s00423-015-1344-5
   PubMed Web of Science ®Google Scholar
• Hiramitsu T, Hasegawa Y, Futamura K, et al. Treatment for secondary hyperparathyroidism focusing on parathyroidectomy. Front Endocrinol. 2023 Apr 14;14. doi: 10.3389/fendo.2023.1169793
   Web of Science ®Google Scholar
• Dulfer RR, Koh EY, van der Plas WY, et al. Parathyroidectomy versus cinacalcet for tertiary hyperparathyroidism; a retrospective analysis. Langenbecks Arch Surg. 2019 Feb;404(1):71–79. doi: 10.1007/s00423-019-01755-4
   PubMed Web of Science ®Google Scholar
• Koh EY, van der Plas WY, Dulfer RR, et al. Outcomes of parathyroidectomy versus calcimimetics for secondary hyperparathyroidism and kidney transplantation: a propensity-matched analysis. Langenbecks Arch Surg. 2020 Sep;405(6):851–859. doi: 10.1007/s00423-020-01953-5
   PubMed Web of Science ®Google Scholar
• van der Plas WY, Dulfer RR, Engelsman AF, et al. Effect of parathyroidectomy and cinacalcet on quality of life in patients with end-stage renal disease-related hyperparathyroidism: a systematic review. Nephrol Dialysis Transplantation. 2017 Nov;32(11):1902–1908. doi: 10.1093/ndt/gfx044
   PubMed Web of Science ®Google Scholar
• Narayan R, Perkins RM, Berbano EP, et al. Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis. Am J Kidney Diseases. 2007 Jun;49(6):801–813. doi: 10.1053/j.ajkd.2007.03.009
   PubMed Web of Science ®Google Scholar
• Komaba H, Moriwaki K, Goto S, et al. Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan. Am J Kidney Diseases. 2012 Aug;60(2):262–271. doi: 10.1053/j.ajkd.2011.12.034
   PubMed Web of Science ®Google Scholar
• Wang AY, Lo WK, Cheung SC, et al. Parathyroidectomy versus oral cinacalcet on cardiovascular parameters in peritoneal dialysis patients with advanced secondary hyperparathyroidism (PROCEED): a randomized trial. Nephrol Dial Transplant. 2023 Jul 31;38(8):1823–1835. doi: 10.1093/ndt/gfad043
   PubMed Web of Science ®Google Scholar
• Wang AY, Tang TK, Yau YY, et al. Impact Of parathyroidectomy versus oral cinacalcet on bone mineral density in patients on peritoneal dialysis with advanced secondary hyperparathyroidism: the PROCEED pilot randomized trial. Am J Kidney Dis. 2024 Apr;83(4):456–466.
   PubMed Web of Science ®Google Scholar
• Fukagawa M, Kitaoka M, Tominaga Y, et al. Guidelines for percutaneous ethanol injection therapy of the parathyroid glands in chronic dialysis patients. Nephrol Dial Transplant. 2003 Jun;18(Suppl 3):iii31–3. doi: 10.1093/ndt/gfg1008
   PubMedGoogle Scholar
• Koiwa F, Hasegawa T, Tanaka R, et al. Indication and efficacy of PEIT in the management of secondary hyperparathyroidism. NDT Plus. 2008 Aug;1(Suppl 3):iii14–iii17. doi: 10.1093/ndtplus/sfn081
   PubMedGoogle Scholar
• Fernández-Martín JL, Carrero JJ, Benedik M, et al. COSMOS: the dialysis scenario of CKD-MBD in Europe. Nephrol Dialysis Transplantation. 2013 Jul;28(7):1922–1935. doi: 10.1093/ndt/gfs418
   PubMed Web of Science ®Google Scholar
• Cozzolino M, Shilov E, Li Z, et al. Pattern Of laboratory parameters and management of secondary hyperparathyroidism in countries of Europe, Asia, the Middle East, and North America. Adv Ther. 2020 Jun;37(6):2748–2762. doi: 10.1007/s12325-020-01359-1
   PubMed Web of Science ®Google Scholar
• Sampson M, Faria N, Powell JJ, et al. Efficacy and safety of PT20, an iron-based phosphate binder, for the treatment of hyperphosphataemia: a randomized, double-blind, placebo-controlled, dose-ranging, Phase IIb study in patients with haemodialysis-dependent chronic kidney disease. Nephrol Dialysis Transplantation. 2021 Aug;36(8):1399–1407. doi: 10.1093/ndt/gfaa116
   PubMed Web of Science ®Google Scholar
• Wu-Wong JR, Chen YW, Wong JT, et al. Preclinical studies of VS-505: a non-absorbable highly effective phosphate binder. Br J Pharmacol. 2016 Jul;173(14):2278–2289. doi: 10.1111/bph.13510
   PubMed Web of Science ®Google Scholar
• Gan L, Zhuang B, Yang J, et al. ABSTRACT: SA-PO173: a dose escalation study to evaluate the tolerability, safety, and efficacy of VS-505 In hemodialysis patients with hyperphosphatemia. J Am Soc Nephrol. 2022;33(11S):650–650. doi: 10.1681/ASN.20223311S1650b
   Google Scholar
• Zhuang B, Gan LY, Liu B, et al. Tolerability, safety, and efficacy of a novel phosphate binder VS-505 (AP301): a Phase 2 dose-escalation and dose-ranging study in patients undergoing maintenance hemodialysis. Nephrol Dialysis Transplantation. 2024 Mar. doi: 10.1093/ndt/gfae053
   PubMed Web of Science ®Google Scholar
• China’s NMPA clears phase 3 IND application for alebund pharmaceutical’s AP301, a new-generation iron-based phosphate binder, to treat hyperphosphatemia in dialysis patients. 2023 cited 2024 Jan 22. Available from: https://www.lillyasiaventures.com/blog/china-s-nmpa-clears-phase-3-ind-application-for-alebund-pharmaceutical-s
   Google Scholar
• Tsuboi Y, Ohtomo S, Ichida Y, et al. EOS789, a novel pan-phosphate transporter inhibitor, is effective for the treatment of chronic kidney disease-mineral bone disorder. Kidney Int. 2020 Aug;98(2):343–354. doi: 10.1016/j.kint.2020.02.040
   PubMed Web of Science ®Google Scholar
• Tanifuji K, Shiozaki Y, Koike M, et al. Effects of EOS789, a novel pan-phosphate transporter inhibitor, on phosphate metabolism: comparison with a conventional phosphate binder. J Med Invest. 2023 Feb;70(1–2):260–270. doi: 10.2152/jmi.70.260
   PubMed Web of Science ®Google Scholar
• Gallant KMH, Stremke ER, Trevino LL, et al. EOS789, a broad-spectrum inhibitor of phosphate transport, is safe with an indication of efficacy in a phase 1b randomized crossover trial in hemodialysis patients. Kidney Int. 2021 May;99(5):1225–1233. doi: 10.1016/j.kint.2020.09.035
   PubMed Web of Science ®Google Scholar
• Alebund Reports Update for AP306 (EOS789), a First-in-Class Pan-inhibitor of Sodium-dependent Phosphate Transporters. From a Completed Phase II clinical trial in patients with hyperphosphatemia on hemodialysis 2023. cited 2024 Jan 22. Available from: https://www.prnewswire.com/news-releases/alebund-reports-update-for-ap306-eos789-a-first-in-class-pan-inhibitor-of-sodium-dependent-phosphate-transporters-from-a-completed-phase-ii-clinical-trial-in-patients-with-hyperphosphatemia-on-hemodialysis-302013538.html
   Google Scholar
• Locatelli F, Dimkovic N, Spasovski G. Colestilan for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Expert Rev Endocrinol Metab. 2015;10(2):131–142. doi: 10.1586/17446651.2015.1009368
   PubMed Web of Science ®Google Scholar
• Negri AL, Brandemburg VM. Calcitriol resistance in hemodialysis patients with secondary hyperparathyroidism. Int Urol Nephrol. 2014 Jun;46(6):1145–1151. doi: 10.1007/s11255-013-0637-2
   PubMed Web of Science ®Google Scholar
• Shevde NK, Plum LA, Clagett-Dame M, et al. A potent analog of 1α,25-dihydroxyvitamin D3 selectively induces bone formation. Proc Natl Acad Sci, USA. 2002 Oct;99(21):13487–13491. doi: 10.1073/pnas.202471299
   PubMed Web of Science ®Google Scholar
• Zella JB, Plum LA, Plowchalk DR, et al. Novel, selective Vitamin D analog suppresses parathyroid hormone in uremic animals and postmenopausal women. Am J Nephrol. 2014;39(6):476–483. doi: 10.1159/000362846
   PubMed Web of Science ®Google Scholar
• Pandey R, Zella JB, Zhu JG, et al. Pharmacokinetics of a new oral vitamin D receptor activator (2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3) in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis. Drugs In R&D. 2017 Dec;17(4):597–605. doi: 10.1007/s40268-017-0210-z
   PubMed Web of Science ®Google Scholar
• DeLuca HF, Bedale W, Binkley N, et al. The vitamin D analogue 2MD increases bone turnover but not BMD in postmenopausal women with osteopenia: results of a 1-year phase 2 double-blind, placebo-controlled, randomized clinical trial. J Bone Miner Res. 2011 Mar;26(3):538–545. doi: 10.1002/jbmr.256
   PubMed Web of Science ®Google Scholar
• Pandey R, Zella J, Clagett-Dame M, et al. Use of 2MD, a novel oral calcitriol analog, in hemodialysis patients with secondary hyperparathyroidism. Am J Nephrol. 2016;43(3):213–220. doi: 10.1159/000445756
   PubMed Web of Science ®Google Scholar
• Thadhani R, Zella JB, Knutson DC, et al. 2MD (DP001), A single agent in the management of hemodialysis patients: a randomized trial. Am J Nephrol. 2017;45(1):40–48. doi: 10.1159/000452680
   PubMed Web of Science ®Google Scholar
• Ma JN, Owens M, Gustafsson M, et al. Characterization of highly efficacious allosteric agonists of the human calcium-sensing receptor. J Pharmacol Exp Ther. 2011 Apr;337(1):275–284. doi: 10.1124/jpet.110.178194
   PubMed Web of Science ®Google Scholar
• Leach K, Gregory KJ, Kufareva I, et al. Towards a structural understanding of allosteric drugs at the human calcium-sensing receptor. Cell Res. 2016 May;26(5):574–592. doi: 10.1038/cr.2016.36
   PubMed Web of Science ®Google Scholar
• Dinh L, DeBono A, Keller AN, et al. Development of AC265347-inspired calcium-sensing receptor ago-positive allosteric modulators. ChemMedchem. 2021 Nov;16(22):3451–3462. doi: 10.1002/cmdc.202100368
   PubMed Web of Science ®Google Scholar
• Bone disease - 1. NDT Plus. 2009;2(suppl_2):ii2065–ii2065. doi: 10.1093/ndtplus/2.s2.32
   Google Scholar
• Wilson BC, Patterson MS. The physics, biophysics and technology of photodynamic therapy. Phys Med Biol. 2008 May;53(9):R61–R109. doi: 10.1088/0031-9155/53/9/R01
   PubMed Web of Science ®Google Scholar
• Wachowska M, Muchowicz A, Firczuk M, et al. Aminolevulinic Acid (ALA) as a prodrug in photodynamic therapy of cancer. Molecules. 2011 May;16(5):4140–4164. doi: 10.3390/molecules16054140
   Web of Science ®Google Scholar
• Prosst RL, Willeke F, Schroeter L, et al. Fluorescence-guided minimally invasive parathyroidectomy: a novel detection technique for parathyroid glands. Surg Endosc. 2006 Sep;20(9):1488–1492. doi: 10.1007/s00464-005-0471-4
   PubMed Web of Science ®Google Scholar
• Miyakogawa T, Kanai G, Tatsumi R, et al. Feasibility of photodynamic therapy for secondary hyperparathyroidism in chronic renal failure rats. Clin Exp Nephrol. 2017 Aug;21(4):563–572. doi: 10.1007/s10157-016-1335-z
   PubMed Web of Science ®Google Scholar
• Wen Y, Zeng LY, Chen QT, et al. RNA-Seq-based transcriptomics analysis during the photodynamic therapy of primary cells in secondary hyperparathyroidism. Photochem Photobiol Sci. 2023 Apr;22(4):905–917. doi: 10.1007/s43630-023-00361-0
   PubMed Web of Science ®Google Scholar
• Martins WK, Belotto R, Silva MN, et al. Autophagy regulation and photodynamic therapy: insights to improve outcomes of cancer treatment. Front Oncol. 2021 Jan 10;10. doi: 10.3389/fonc.2020.610472
   Web of Science ®Google Scholar
• Zeng LY, Zou QY, Huang P, et al. Inhibition of autophagy with Chloroquine enhanced apoptosis induced by 5-aminolevulinic acid-photodynamic therapy in secondary hyperparathyroidism primary cells and organoids. Biomed Pharmacother. 2021 Oct;142:111994. doi: 10.1016/j.biopha.2021.111994
   PubMed Web of Science ®Google Scholar
• Friedrich M, Pracht K, Mashreghi MF, et al. The role of the miR-148/-152 family in physiology and disease. Eur J Immunol. 2017 Dec;47(12):2026–2038. doi: 10.1002/eji.201747132
   PubMed Web of Science ®Google Scholar
• Melkman-Zehavi T, Oren R, Kredo-Russo S, et al. miRNAs control insulin content in pancreatic β-cells via downregulation of transcriptional repressors. Embo J. 2011 Mar;30(5):835–845. doi: 10.1038/emboj.2010.361
   PubMed Web of Science ®Google Scholar
• Deng BP, Tang X, Wang Y. Role of microRNA-129 in cancer and non-cancerous diseases (Review). Exp Ther Med. 2021 Sep;22(3). doi: 10.3892/etm.2021.10350
   Web of Science ®Google Scholar
• Xu MZ, Li H, Bai YF, et al. miR-129 blocks secondary hyperparathyroidism-inducing Fgf23/αKlotho signaling in mice with chronic kidney disease. Am J Med Sci. 2021 May;361(5):624–634. doi: 10.1016/j.amjms.2020.09.013
   PubMed Web of Science ®Google Scholar
• Chesnaye NC, Carrero JJ, Hecking M, et al. Differences in the epidemiology, management and outcomes of kidney disease in men and women. Nat Rev Nephrol. 2024 Jan;20(1):7–20. doi: 10.1038/s41581-023-00784-z
   PubMed Web of Science ®Google Scholar
• Galassi A, Ciceri P, Fasulo E, et al. Management of secondary hyperparathyroidism in chronic kidney disease: a focus on the elderly. Drugs Aging. 2019 Oct;36(10):885–895. doi: 10.1007/s40266-019-00696-3
   PubMed Web of Science ®Google Scholar
• Magagnoli L, Galassi A, Cozzolino M. Beyond vessels and bones: can CKD-MBD treatment improve uraemic subjects’ minds? Nephrol Dialysis Transplantation. 2022 Oct;37(11):2039–2041. doi: 10.1093/ndt/gfac176
   PubMed Web of Science ®Google Scholar